Get Articles Daily from StraightStocks - Enter Email Address


  • National Debt Clock


Isis Pharma Maintains a Buy – Analyst Blog

Source: http://www.zacks.com/stock/news/17790/Isis+Pharma+Maintains+a+Buy+-+Analyst+Blog
 Posted on Friday, February 27th, 2009 | In Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -

We are reiterating or rating on Isis Pharmaceuticals (ISIS) of a Buy and maintaining our price target of $22.

We believe that antisense technology represents an exciting and potentially revolutionary platform for developing therapeutic candidates to treat a wide margin of diseases. In our view, antisense as a platform is today where biologics were 10 years ago.

The company’s leading candidates are mipomersen (w/ Genzyme, GENZ) for high cholesterol and ISIS-113715 for diabetes, along with several other proprietary and partnered programs for oncology, inflammatory disease, asthma, and viral infections. Our financial model forecasts sustained profitability in 2011.

Read the full analyst report on “ISIS”
Zacks Investment Research

Last 5 posts by Zacks Market Commentaries
About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries

Leave a Reply

Name

Email (kept private)

Website









No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.